摘要
目的探讨左西孟旦对心脏外科术后因左心功能不全应用主动脉内球囊反搏(IABP)患者预后的影响。方法收集2015年7月至2017年3月首都医科大学附属北京安贞医院心脏外科术后24 h内出现左心功能不全应用IABP的205例患者的临床资料进行回顾性分析。依据是否应用左西孟旦分为左西孟旦组(90例)和对照组(115例)。经倾向性评分匹配,比较2组患者的住院病死率、机械通气时间、IABP辅助时间、住院时间等。结果经倾向性评分匹配后,共有128例患者纳入研究(2组各64例)。左西孟旦组与对照组间主要终点住院病死率比较,无论倾向性评分匹配前[21. 1%(19/90)比27. 8%(32/115)]还是匹配后[21. 9%(14/64)比21. 9%(14/64)],差异均无统计学意义(均P> 0. 05)。经倾向性评分匹配后次要终点比较,左西孟旦组的机械通气时间、IABP辅助时间均明显短于对照组[(134±119) h比(254±271) h、(5±2) d比(7±4) d],差异均有统计学意义(均P <0. 05)。然而,住院时间以及术后并发症发生率在2组间差异无统计学意义(P> 0. 05)。结论左西孟旦不能降低心脏外科术后左心功能不全应用IABP辅助患者的住院病死率,但可以缩短患者的机械通气时间及IABP辅助时间。
Objective To investigate the effect of levosimendan on patients with left heart dysfunction supported by intra-aortic balloon pump(IABP) after cardiac surgery. Methods Clinical data of 205 patients who had left heart dysfunction within 24 hours after cardiac surgery supported by IABP in Beijing Anzhen Hospital, Capital Medical University from July 2015 to March 2017 were retrospectively analyzed. The patients were divided into levosimendan group(n=90) and control group(n=115). In-hospital mortality, mechanical ventilation time, IABP time and hospitalization time were analyzed. Results After propensity score matching, 128 patients were finally included, with 64 cases in each group. There was no significant difference of in-hospital mortality between groups before and after propensity score matching[21.1%(19/90) vs 27.8%(32/115), 21.9%(14/64) vs 21.9%(14/64)](P>0.05). After propensity score matching, mechanical ventilation time and IABP time in levosimendan group were significantly shorter than those in control group[(134±119)h vs (254±271)h, (5±2)d vs (7±4)d](P<0.05). Hospitalization time and postoperative complication rate showed no significant difference between groups(P>0.05). Conclusion Levosimendan can not reduce the in-hospital mortality in patients with left heart dysfunction supported by IABP after cardiac surgery, but the mechanical ventilation time and IABP use time can be shortened.
作者
刘亚洲
侯晓彤
贾明
王红
李呈龙
Liu Yazhou;Hou Xiaotong;Jia Ming;Wang Hong;Li Chenglong(Intensive Care Center,Department of Cardiac Srugery,Beijing Anzhen Hospital,Capital Medical University,Bering Institute of Heart Lung and Blood Vessel Diseases,Beijing 100029,China)
出处
《中国医药》
2019年第2期200-204,共5页
China Medicine
基金
国家重点研发计划(2016YFC1301001)~~